Pediatric Hand Transplantation: A Decision Analysis

• Published in: Hand (New York, N.Y.) Vol. 16; no. 6; pp. 731 - 740
• Main Authors: Snyder, Kaitlyn J. G., Amaral, Sandra, Kessler, Sudha, Lefkowitz, Debra, Levy, Todd J., Hewlett, Jennifer, Levin, Scott, Feudtner, Chris
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.11.2021
• Subjects: Adult; Child; Cost-Benefit Analysis; Decision Support Techniques; Hand - surgery; Hand Transplantation; Humans; Quality-Adjusted Life Years; Surgery; hand transplantation; vascular composite allograph; decision analysis; pediatric
• ISSN: 1558-9447; 1558-9455
• DOI: 10.1177/1558944719890041

Background: The first successful bilateral pediatric hand transplant was performed in 2015. Previous hand transplant decision analysis models have focused on the adult population. This model principally aimed to determine whether adverse outcomes associated with immunosuppression outweigh the benefits of performing bilateral hand transplant surgery in a pediatric candidate. The model also conceptualized the valuation of losing years of life and sought to determine the impact of that valuation on the surgical decision. Methods: A decision model compared undergoing bilateral hand transplant surgery with using prosthetics for an 8-year-old patient. The outcome measure used was quality adjusted life years (QALYs), and sensitivity analysis was performed on the immunosuppressive risks associated with the surgical decision, as well as the perceived valuation of aversion to life years lost. Results: The decision to perform surgery was marginally optimal compared to the prosthetic decision (50.11 QALY vs. 47.95 QALY). A Monte Carlo simulation revealed that this difference may be too marginal to detect an optimal decision (50.14 ± 8.28 QALY vs. 47.95 ± 2.12 QALY). Sensitivity analysis identified decision thresholds related to immunosuppression risks (P = 29% vs. P = 33% modeled), and a trend of increasing risk as a patient is more averse to losing life years. Conclusions: The marginally optimal treatment strategy currently is bilateral hand transplant, compared to prosthetics for pediatric patients. Key determinants of the future optimal strategy will be whether immunosuppressive regimens become safer, with a reduced risk of losing life years due to immunosuppressive complications, and whether prosthetics become more acceptable and enable higher functioning.